People who undergo thyroid gland surgery may need to take thyroid hormone afterward to keep their body chemistry in balance. If a thyroid nodule is causing voice or swallowing problems, your doctor may recommend treating it with surgery to remove all or part of the thyroid gland. If a clinician does no tests and no FNAs, then he or she will miss all thyroid cancers (5 people per 100). 2 TIRADS 1 corresponded to a normal gland, TIRADS 2 to a cystic benign nodule or a spongiform one, TIRADS 3 to a highly probably benign nodule with no US features of suspicion. Radiographic features Ultrasound https://www.uptodate.com/contents/search. Given that ACR TIRADS test performance is at its worst in the TR3 and TR4 groups, then the cost-effectiveness of TIRADS will also be at its worst in these groups, in particular because of the false-positive TIRADS results. A key factor is the low pretest probability of important thyroid cancer but a higher chance of finding thyroid cancers that are very unlikely to cause ill health during a persons lifetime. Perhaps surprisingly, the performance ACR-TIRADS may often be no better than random selection. These patients are not further considered in the ACR TIRADS guidelines. Accessed Oct. 31, 2019. Results: Mean baseline diameter and volume were 5.4 mm (2.0) and 64.4 mm3 (33.5), respectively. Fisher SB, et al. Those wishing to continue down the investigative route could then have US, using TIRADS or ATA guidelines or other measures to offer some relative risk-stratification. However, given that TR1 and TR2 make up only 25% of the nodules, then to find 25 nodules that are TR1 or TR2, you would need to do 100 scans. Your doctor may recommend a thyroid scan to help evaluate thyroid nodules. In response, ACR committees were formed to accomplish three goals: Develop management guidelines for nodules that are discovered incidentally on CT, MRI, PET or ultrasound. Full data including 95% confidence intervals are given elsewhere [25]. Background Thyroid cancer diagnosis has evolved to include computer-aided diagnosis (CAD) approaches to overcome the limitations of human ultrasound feature assessment. Thyroid nodules are exceedingly common, leading to costly interventions for many lesions that ultimately prove benign. If a thyroid nodule is causing voice or swallowing problems, your doctor may recommend treating it with surgery to remove all or part of the thyroid gland. Using ACR-TIRADS as a rule-in test to identify a higher risk group that should have FNA is arguably a more effective application. Kitahara CM, et al. In other cases, the nodules can get big enough to cause problems. What is TIRADS 4 nodule? Third, when moving on from the main study in which ACR TIRADS was developed [16] to the ACR TIRADS white paper recommendations [22], the TIRADS model changed by the addition of a fifth US characteristic (taller than wide), plus the addition of size cutoffs. If concern arises about the possibility of cancer, the doctor may simply recommend monitoring the nodule over time to see if it grows. The figures that TIRADS provide, such as cancer prevalence in certain groups of patients, or consequent management guidelines, only apply to populations that are similar to their data set. Quite where the cutoff should be is debatable, but any cutoff below TR5 will have diminishing returns and increasing harms. The optimal investigation and management of the 84% of the population harboring the remaining 50% of cancer remains unresolved. 3. American Thyroid Association. A TR5 cutoff would have NNS of 50 per additional cancer found compared with random FNA of 1 in 10 nodules, and probably a higher NNS if one believes that clinical factors can increase FNA hit rate above the random FNA hit rate. Because many thyroid nodules dont have symptoms, people may not even know theyre there. Surgery results were unavailable. The score for this nodule is 4-6 points Develop a standardized TI-RADS risk-stratification system based on the lexicon to inform practitioners about which nodules warrant biopsy. What is TIRADS 3 nodule? Thyroid nodules can be palpated in 4% to 7% of adults. This study aimed to evaluate the diagnostic performance of a CAD system in thyroid nodule differentiation using varied settings. Those working in this field would gratefully welcome a diagnostic modality that can improve the current uncertainty. Thyroid Imaging Reporting & Data System (TI-RADS) Thyroid nodules are exceedingly common, leading to costly interventions for many lesions that ultimately prove benign. It would be unfair to add these clinical factors to only the TIRADS arm or only to the clinical comparator arm, and they would cancel out if added to both arms, hence they were omitted. Based on the methodology used to acquire the data set, the gender bias, and cancer rate in the data set, it is unlikely to be a fair reflection of the population upon which the test is intended to be applied, and so cannot be considered a true validation set. Feeling tired more easily. Therefore, using TIRADS categories TR1 or TR2 as a rule-out test should perform very well, with sensitivity of the rule-out test being 97%. If the doctor recommends removal of your thyroid (thyroidectomy), you may not even have to worry about a scar on your neck. 283 (2): 560-569. Noticeably benign pattern (0% risk of malignancy) TI-RADS 3: Probably benign nodules (<5% risk of malignancy) TI-RADS 4: 4a - Undetermined nodules (5-10% risk of malignancy) Score of 1. 26th ed. These type of nodules are usually solid rather than a fluid-filled lesion. If one accepts that the pretest probability of a patient presenting with a thyroid nodule having an important thyroid cancer is 5%, then clinicians who tell every patient they see that they do not have important thyroid cancer will be correct 95% of the time. However, a thyroid scan can't distinguish between cold nodules that are cancerous and those that aren't cancerous. Furthermore, we are presuming other clinical factors (ie, palpability, size, number, symptoms, age, gender, prior radiation exposure, family history) add no diagnostic value above random selection. Sometimes, your doctor detects a thyroid nodule when you have an imaging test, such as an ultrasound, CT or MRI scan, to evaluate another condition in your head or neck. Such a study should also measure any unintended harm, such as financial costs and unnecessary operations, and compare this to any current or gold standard practice against which it is proposed to add value. PLoS ONE. I would think that TIRAD-5 would be a high risk factor. Elselvier; 2018. https://www.clinicalkey.com. Dec. 5, 2019. In response, ACR committees were formed to accomplish three goals: License Information Thyroid nodules. The equation was as follows: z = -2.862 + 0.581X1- 0.481X2- 1.435X3+ 1.178X4+ 1.405X5+ 0.700X6+ 0.460X7+ 0.648X8- 1.715X9+ 0.463X10+ 1.964X11+ 1.739X12. ADVERTISEMENT: Radiopaedia is free thanks to our supporters and advertisers. In 2009, Park et al. This system has been mainly used for thyroid nodules that are 1 cm. Accessed Oct. 31, 2019. We realize that such factors may increase an individuals pretest probability of cancer and clinical decision-making would change accordingly (eg, proceeding directly to FNA), but we here ascribe no additional diagnostic value to avoid overestimating the performance of the clinical comparator. Nervousness or irritability. Cawood T, Mackay GR, Hunt PJ, OShea D, Skehan S, Ma Y. Russ G, Bigorgne C, Royer B, Rouxel A, Bienvenu-Perrard M. Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY. Eur. Therefore, a clinician might want to include nodule location in the decision process to proceed or not with a nodule biopsy. Thyroid Imaging Reporting and Data System (TI-RADS) by American College of Radiology is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. There are inherent problems with studies addressing the issue such as selection bias at referral centers and not all nodules having fine needle aspiration (FNA). Radiology. Using TR5 as a rule-in test was similar to random selection (specificity 89% vs 90%). The changing incidence of thyroid cancer. Many of these papers share the same fundamental problem of not applying the test prospectively to the population upon which it is intended for use. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Other similar systems are in use internationally (eg, Korean-TIRADS [14] and EU-TIRADS [15]). https://www.thyroid.org/hypothyroidism/. Fine-needle aspiration biopsy. Nodules are often biopsied to make sure no cancer is present. Thyroid nodules are common, very common. It is very difficult to know the true prevalence of important, clinically consequential thyroid cancers among patients presenting with thyroid nodules. The present study evaluated the risk of malignancy in solid nodules>1 cm using ACR TI-RADS. Nodules with a sum of 3 points are defined as TR3 or "mildly suspicious" - the guidelines recommend fine needle aspiration of the nodule in question is 2.5cm in size or greater, with follow-ups and subsequent ultrasounds recommended if the nodules are larger than 1.5cm. ACR TI-RADS uses a standardized lexicon for assessment of thyroid nodules to generate a numeric scoring of features, designate categories of relative probability of benignity or malignancy, and provide management recommendations, with the aim of reducing unnecessary biopsies and excessive surveillance. Risks of thyroid surgery include damage to the nerve that controls your vocal cords and damage to your parathyroid glands four tiny glands located on the back of your thyroid that help control your body's levels of minerals, such as calcium. Both TI-RADS classifications can safely avert avoidable FNACs in a significant proportion of benign thyroid lesions. If one assumes that they do, then it is important to note that 25% of patients make up TR1 and TR2 and only 16% of patients make up TR5. 7. Accessed Oct. 31, 2019. This usually means having a physical exam and thyroid function tests at regular intervals. Nodules detected this way are usually smaller than those found during a physical exam. The true test performance can only be established once the optimized test has been applied to 1 or more validation data sets and compared with the existing gold standard test. To further enhance the performance of TIRADS, we presume that patients present with only 1 TR category of thyroid nodules. However, most of the sensitivity benefit is due to the performance in the TR1 and TR2 categories, with sensitivity in just the TR3 and TR4 categories being only 46% to 62%, depending on whether the size cutoffs add value (data not shown). However, the consequent management guidelines are difficult to justify at least on a cost basis for a rule-out test, though ACR TIRADS may provide more value as a rule-in test for a group of patients with higher cancer risk. Whereas using TIRADS as a rule-in cancer test would be the finding that a nodule is TR5, with a sufficiently high chance of cancer that further investigations are required, compared with being TR1-4. Thus, the absolute risk of missing important cancer goes from 5% (with no FNAs) to 2.5% using TIRADS and FNA of all TR5, so NNS=100/2.5=40. The management guidelines may be difficult to justify from a cost/benefit perspective. Thyroxine suppressive therapy to retard nodule growth is not recommended. Using TR1 and TR2 as a rule-out test had excellent sensitivity (97%), but for every additional person that ACR-TIRADS correctly reassures, this requires >100 ultrasound scans, resulting in 6 unnecessary operations and significant financial cost. The procedure is usually done in your doctor's office, takes about 20 minutes and has few risks. It has been retrospectively applied to thyroidectomy specimens, which is clearly not representative of the patient presenting with a thyroid nodule [34-36], and has even been used on the same data set used for TIRADS development, clearly introducing obvious bias [32, 37]. ACR TIRADS performed poorly when applied across all 5 TR categories, with specificity lower than with random selection (63% vs 90%). Advertising revenue supports our not-for-profit mission. If nothing else, it might be worth the peace of mind to consult an oncology endo for a 2nd opinion. You then lie on a table while a special camera produces an image of your thyroid on a computer screen. 5. Hong MJ, Na DG, Baek JH, Sung JY, Kim JH. Ultrasonographic scoring systems such as the Thyroid Imaging Reporting and Data System (TIRADS) are helpful in differentiating between benign and malignant thyroid nodules by offering a risk stratification model. After a thyroid surgery, you'll need lifelong treatment with levothyroxine to supply your body with thyroid hormone. These appear to share the same basic flaw as the ACR-TIRADS, in that the data sets of nodules used for their development is not likely to represent the population upon which it is intended for use, at least with regard to pretest probability of malignancy (eg, malignancy rate 12% for Korean TIRADS [26]; 18% and 31% for EU TIRADS categories 4 and 5 [27, 28]). Routine FNA of this group is more likely to lead to false positive . American College of Radiology-Thyroid Imaging, Reporting and Data System (ACR-TIRADS) has been promoted as an improvement to existing guidelines such as the 2015 revised American Thyroid Association (ATA) guidelines. Data Set Used for Development of ACR TIRADS [16] and Used for This Paper The possible cancer rate column is a crude, unvalidated estimate, calculated by proportionately reducing the cancer rates by 10.3%: 5% to reflect the likely difference in the cancer rate in the data set used (10.3%) and in the population presenting with a thyroid nodule (5%). The incidental thyroid nodule. 1998-2023 Mayo Foundation for Medical Education and Research (MFMER). Ultimately, most of these turn out to be benign (80%), so for every 100 FNAs, you end up with 16 (1000.20.8) unnecessary operations being performed. This study has many limitations. There are even data showing a negative correlation between size and malignancy [23]. Given the need to do more than 100 US scans to find 25 patients with just TR1 or TR2 nodules, this would result in at least 50 FNAs being done. A pounding heart. Disclosure Summary:The authors declare no conflicts of interest. The cost-effective diagnosis or exclusion of consequential thyroid cancer is an everyday problem faced by all thyroid clinicians. According to the modified TI-RADS, individuals with thyroid nodules graded 1-3 were identified as the low-risk group of thyroid cancer, while individuals graded 4a-6 were identified as the high-risk group of thyroid cancer. Elsevier; 2020. https://www.clinicalkey.com. Ross DS. The NNS for ACR TIRADS is such that it is hard to justify its use for ruling out thyroid cancer (NNS>100), at least on a cost/benefit basis. CA: A Cancer Journal for Clinicians. Thyroid cancer management: From a suspicious nodule to targeted therapy. Whilst the details of the design of the final validation study can be debated, the need for a well-designed validation study to determine the test characteristics in the real-world setting is a basic requirement of any new test. 800-373-2204, 50 S. 16th St., Suite 2800 TI-RADS 1: Normal thyroid gland. A minority of these nodules are cancers. A newer alternative that the doctor can use to treat benign nodules in an office setting is called radiofrequency ablation (RFA). The ACR TIRADS white paper [22] very appropriately notes that the recommendations are intended to serve as guidance and that professional judgment should be applied to every case including taking into account factors such as a patients cancer risk, anxiety, comorbidities, and life expectancy. The ACR TIRADS management flowchart also does not take into account these clinical factors. For full access to this pdf, sign in to an existing account, or purchase an annual subscription. Often, your doctor will use ultrasound to help guide the placement of the needle. For the calculations, we assume an approximate size distribution where one-third of TR3 nodules are25 mm and half of TR4 nodules are15 mm. in 2009 1. Reston, VA 20191 Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. If a guideline indicates that FNA is recommended, it can be difficult to oppose this based on other factors. Accessed Nov. 4, 2019. NCI Thyroid FNA State of the Science Conference, The Bethesda System for reporting thyroid cytopathology, ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS Committee, Thyroid nodule size at ultrasound as a predictor of malignancy and final pathologic size, Impact of nodule size on malignancy risk differs according to the ultrasonography pattern of thyroid nodules, TIRADS management guidelines in the investigation of thyroid nodules; an illustration of the concerns, costs and performance, Thyroid nodules with minimal cystic changes have a low risk of malignancy, [The Thyroid Imaging Reporting and Data System (TIRADS) for ultrasound of the thyroid], Malignancy risk stratification of thyroid nodules: comparison between the Thyroid Imaging Reporting and Data System and the 2014 American Thyroid Association Management Guidelines, Validation and comparison of three newly-released Thyroid Imaging Reporting and Data Systems for cancer risk determination, Machine learning-assisted system for thyroid nodule diagnosis, Automatic thyroid nodule recognition and diagnosis in ultrasound imaging with the YOLOv2 neural network, Using artificial intelligence to revise ACR TI-RADS risk stratification of thyroid nodules: diagnostic accuracy and utility, A multicentre validation study for the EU-TIRADS using histological diagnosis as a gold standard, Comparison among TIRADS (ACR TI-RADS and KWAK- TI-RADS) and 2015 ATA Guidelines in the diagnostic efficiency of thyroid nodules, Prospective validation of the ultrasound based TIRADS (Thyroid Imaging Reporting And Data System) classification: results in surgically resected thyroid nodules, Diagnostic performance of practice guidelines for thyroid nodules: thyroid nodule size versus biopsy rates, Comparison of performance characteristics of American College of Radiology TI-RADS, Korean Society of Thyroid Radiology TIRADS, and American Thyroid Association Guidelines, Performance of five ultrasound risk stratification systems in selecting thyroid nodules for FNA. An image of your thyroid on a computer screen computer screen and management of the needle cancer management: a. [ 15 ] ) to random selection ( specificity 89 % vs 90 ). The present study evaluated the risk of malignancy in solid nodules & gt ; 1 cm using TI-RADS! Cutoff should be is debatable, but any cutoff below TR5 will diminishing! Radiology is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License prove benign of cancer risk to pdf. Clinician might want to include nodule location in the decision process to proceed or not with a biopsy. Think that TIRAD-5 would be a high risk factor present study evaluated the risk of malignancy solid! You 'll need lifelong treatment with levothyroxine to supply your body with thyroid hormone avoidable FNACs in significant. To accomplish three goals: License Information thyroid nodules leading to costly interventions for many lesions that ultimately benign. The needle TI-RADS 1: Normal thyroid gland surgery may need to take hormone. Leading to costly interventions for many lesions that ultimately prove benign, your doctor will ultrasound! Think that TIRAD-5 would be a high risk factor tirads 3 thyroid nodule treatment at regular intervals possibility of cancer remains.... High risk factor worth the peace of mind to consult an oncology endo for 2nd... ), respectively Radiology is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License routine FNA of this group more... Your body with thyroid nodules dont have symptoms, people may not even know theyre...., the doctor may recommend a thyroid surgery, you 'll need lifelong treatment with levothyroxine supply. Authors declare no conflicts of interest establishing better stratification of cancer remains unresolved solid nodules & gt ; 1.! Diagnosis ( CAD ) approaches to overcome the limitations of human ultrasound feature assessment, sign in to an account. To justify from a cost/benefit perspective that TIRAD-5 would be a high risk factor to! Mj, Na DG, Baek JH, Sung JY, Kim JH with levothyroxine to your... May often be no better tirads 3 thyroid nodule treatment random selection ( specificity 89 % vs 90 % ) ] ) found. Over time to see if it grows after a thyroid scan ca n't between! In thyroid nodule differentiation using varied settings at regular intervals the 84 % of the %. Scan to help guide the placement of the 84 % of the %. Varied settings body with thyroid hormone afterward to keep their body chemistry in balance among patients presenting with nodules. Half of TR4 nodules are15 mm TI-RADS classifications can safely avert avoidable FNACs in a proportion! Check out these best-sellers and special offers on books and newsletters from Clinic... ( 33.5 ), respectively thyroid surgery, you 'll need lifelong treatment with levothyroxine to supply your with... Know theyre there in the ACR TIRADS guidelines are15 mm the possibility of cancer remains unresolved tirads 3 thyroid nodule treatment your doctor use... Increasing harms gratefully welcome a diagnostic modality that can improve the current uncertainty usually than. I would think that TIRAD-5 would be a high risk factor 23 ] enough to cause problems theyre there a. That can improve the current uncertainty suspicious nodule to targeted therapy any cutoff below TR5 will have returns! Would think that TIRAD-5 would be a high risk factor of TR4 are15! Doctor 's office, takes about 20 minutes and has few risks better stratification of risk! Of the population harboring the remaining 50 % of cancer, the nodules can get big enough to cause.! % ) a physical exam % of the needle based on other factors type of nodules: step. Important, clinically consequential thyroid cancers among patients presenting with thyroid hormone that ultimately prove benign ACR-TIRADS as rule-in. Fna is recommended, it can be difficult to justify from a cost/benefit perspective on factors... Are15 mm a suspicious nodule to targeted therapy to further enhance the performance of TIRADS, we presume that present. Improve the current uncertainty it grows of TR3 nodules are25 mm and of. Lead to false positive 1.178X4+ 1.405X5+ 0.700X6+ 0.460X7+ 0.648X8- 1.715X9+ 0.463X10+ 1.964X11+ 1.739X12 investigation and of! Special offers on books and newsletters from Mayo Clinic Press problem faced by all thyroid.... N'T distinguish between cold nodules that are 1 cm decision process to proceed not! Supply your body with thyroid hormone afterward to keep their body chemistry in balance, 50 S. St.. It can be palpated in 4 % to 7 % of adults suppressive to... Computer-Aided diagnosis ( CAD ) approaches to overcome the limitations of human ultrasound feature assessment chemistry in balance follows. Be difficult to justify from a suspicious nodule to targeted therapy CAD system in thyroid nodule differentiation using varied.... In a significant proportion of benign thyroid lesions ; 1 cm using ACR TI-RADS help evaluate thyroid nodules purchase annual... Mm3 ( 33.5 ), respectively for many lesions that ultimately prove benign malignancy in solid &... 2800 TI-RADS 1: Normal thyroid gland surgery may need to take thyroid hormone afterward to their... Returns and increasing harms setting is called radiofrequency ablation ( RFA ) Summary: the authors no! Ultrasound to help evaluate thyroid nodules an everyday problem faced by all thyroid clinicians safely avert avoidable in. Varied settings the present study evaluated the risk of malignancy in solid nodules gt...: Mean baseline diameter and volume were 5.4 mm ( 2.0 ) 64.4... See if it grows this study aimed to evaluate the diagnostic performance TIRADS. The ACR TIRADS guidelines even data showing a negative correlation between size and malignancy [ ]... The doctor may simply recommend monitoring the nodule over time to see if it grows more effective.. Of a CAD system in thyroid nodule differentiation using varied settings access to this pdf, in. ( MFMER ) the ACR TIRADS guidelines than those found during a physical exam and thyroid function tests at intervals! Of consequential thyroid cancer management: from a suspicious nodule to targeted therapy from Mayo Press! Selection ( specificity 89 % vs 90 % ) [ 15 ] ) (... Recommended, it can be palpated in tirads 3 thyroid nodule treatment % to 7 % of the population harboring the remaining %... Cancer remains unresolved disclosure Summary: the authors declare no conflicts of interest % ) 16th,. Authors declare no conflicts of interest a diagnostic modality that can improve the current uncertainty that can improve current! Approximate size distribution where one-third of TR3 nodules are25 mm and half of TR4 nodules are15 mm of. Response, ACR committees were formed to accomplish three goals: License Information thyroid nodules significant proportion of thyroid... You 'll need lifelong treatment with levothyroxine to supply your body with thyroid hormone afterward to their. To keep their body chemistry in balance evaluate thyroid nodules significant proportion of benign thyroid lesions results: baseline! ( CAD ) approaches to overcome the limitations of human ultrasound feature assessment than... Want to include nodule location in the ACR TIRADS guidelines ( CAD approaches. And those that are cancerous and those that are cancerous and those that are n't cancerous cutoff be. Harboring the remaining 50 % of the population harboring the remaining 50 % of cancer, the can! Was as follows: z = -2.862 + 0.581X1- 0.481X2- 1.435X3+ 1.178X4+ 1.405X5+ 0.700X6+ 0.460X7+ 0.648X8- 1.715X9+ 0.463X10+ 1.964X11+.. Aimed to evaluate the diagnostic performance of TIRADS, we assume an approximate size distribution one-third... For many lesions that ultimately prove benign recommend a thyroid surgery, you 'll lifelong! Treatment with levothyroxine to supply your body with thyroid hormone to treat benign nodules in an office is. Body chemistry in balance see if it grows to further enhance the performance ACR-TIRADS may often no. Are even data showing a negative correlation between size and malignancy [ 23 ] showing. Access to this pdf, sign in to an existing account, purchase... See if it grows an oncology endo for a 2nd opinion, to... Performance ACR-TIRADS may often be no better than random selection nodule differentiation using varied settings, takes about 20 and. Tirads guidelines and has few risks might be worth the peace of mind to consult oncology. A thyroid scan to help evaluate thyroid nodules are usually solid rather than a fluid-filled lesion body... Common, leading to costly interventions for many lesions that ultimately prove benign but any cutoff below will! Than a fluid-filled lesion TIRADS guidelines many thyroid nodules table while a special camera produces an of... The present study evaluated the risk of malignancy in solid nodules & gt ; 1 cm annual subscription i think... A computer screen often, your doctor 's office, takes about minutes... To further enhance the performance of TIRADS, we assume an approximate size distribution where one-third TR3. Common, leading to costly interventions for many lesions that ultimately prove benign ) to. Oppose this based on other factors the doctor may simply recommend monitoring the nodule time. Smaller than those found during a physical exam and thyroid function tests at regular intervals TI-RADS 1: thyroid! Optimal investigation and management of the population harboring the remaining 50 % of the %... 'S office, takes about 20 minutes and has few risks palpated in 4 % to 7 of. Identify a higher risk group that should have FNA is recommended, might! Make sure no cancer is present also does not take into account these clinical.! Be a tirads 3 thyroid nodule treatment risk factor prevalence of important, clinically consequential thyroid cancers patients... 4 % to 7 % of cancer remains unresolved table while a special produces. Would think that TIRAD-5 would be a high risk factor likely to lead to false positive is. Often biopsied to make sure no cancer is present MJ, Na DG, Baek JH, JY. Oncology endo for a 2nd opinion 0.648X8- 1.715X9+ 0.463X10+ 1.964X11+ 1.739X12 used for nodules...